Skip to contentP
Processa Pharmaceuticals, Inc.
P
PCSAProcessa Pharmaceuticals, Inc. Q1 2026 · 10-Q
Revenue—
Net Income-$3.38M-$3.38MN/M vs Q1 2025 EPS Diluted-$1.29-$1.29N/M vs Q1 2025 Operating Income-$3,331,214N/M Operating Cash Flow-$3,590,695N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Processa Pharmaceuticals, Inc. · CIK 1533743 · Engraved from SEC EDGAR
ended Mar 31, 2026 · filed May 7, 2026 · 37 d after period end